Amundi Reduces Holdings in Moderna, Inc. $MRNA

Key Points

• Amundi cut its Moderna stake by 20.9% in the first quarter, selling 238,790 shares and retaining 904,823 shares worth approximately $46 million. Institutional investors collectively own 75.33% of Moderna.
• Analyst sentiment remains cautious: Moderna has an average “Reduce” rating and a consensus price target of $40, with two Buy, ten Hold, and five Sell ratings.
• Moderna’s latest results beat reduced earnings expectations, but the company continues to face substantial losses, declining COVID-19 vaccine demand, and a setback in its Phase 3 norovirus vaccine trial.

Amundi lowered its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 20.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 904,823 shares of the company's stock after selling 238,790 shares during the quarter. Amundi owned about 0.23% of Moderna worth $45,965,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. MUFG Securities EMEA plc bought a new position in shares of Moderna during the second quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Moderna during the 4th quarter worth approximately $31,000. Canton Hathaway LLC purchased a new position in Moderna during the 1st quarter valued at $31,000. EverSource Wealth Advisors LLC boosted its holdings in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company's stock valued at $37,000 after acquiring an additional 801 shares during the period. Finally, Kelleher Financial Advisors bought a new position in Moderna in the 4th quarter valued at $39,000. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MRNA shares. Wolfe Research reiterated an "underperform" rating and issued a $25.00 target price on shares of Moderna in a research note on Monday, July 20th. Morgan Stanley boosted their target price on shares of Moderna from $33.00 to $39.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 8th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Moderna in a research note on Thursday, June 18th. Piper Sandler lifted their price objective on shares of Moderna from $69.00 to $77.00 and gave the company an "overweight" rating in a report on Friday, June 26th. Finally, The Goldman Sachs Group lifted their price objective on shares of Moderna from $49.00 to $67.00 and gave the company a "neutral" rating in a report on Tuesday, July 21st. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus target price of $40.00.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Insider Activity

In other Moderna news, President Stephen Hoge sold 53,336 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 119,406 shares of company stock worth $5,928,762. 10.80% of the stock is currently owned by corporate insiders.

Moderna Stock Performance

Shares of Moderna stock opened at $54.82 on Monday. The firm has a market cap of $21.75 billion, a P/E ratio of -6.86 and a beta of 0.91. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $85.60. The stock's fifty day moving average price is $59.37 and its 200-day moving average price is $52.64.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the prior year, the firm earned ($2.13) earnings per share. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.